73 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
, a novel and proprietary state-of-the-art delivery system for pegfilgrastim-cbqv, was launched in February 2024. High customer demand coupled
8-K
EX-2.1
CHRS
Coherus Biosciences Inc
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
, financial, marketing and business data, pricing and cost information, business and marketing plans, customer and supplier lists and information, and all … with GAAP and reflect all estimated customer and Governmental Authority-mandated discounts.
(g) [***].
Section 3.7 Undisclosed Liabilities
8-K/A
EX-99.1
1k9piiebstuot4
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
425
af62gyuo
16 Jun 23
Business combination disclosure
8:08am
425
rk5ewunnz9v1fxh9549
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
t0yb gbqh
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-10.1
cc7 j02ti
7 Jan 22
Coherus BioSciences Secures Credit Financing
8:36am